Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 336

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Advani, Anjali, Coiffier, Bertrand, Czuczman, Myron S., Dreyling, Martin, Foran, James, Gine, Eva, Gisselbrecht, Christian, Ketterer, Nicolas, Nasta, Sunita, Rohatiner, Ama, Schmidt-Wolf, Ingo G.H., Schuler, Martin, Sierra, Jorge, Smith, Mitchell R., Verhoef, Gregor, Winter, Jane N., Boni, Joseph, Vandendries, Erik, Shapiro, Mark, Fayad, Luis·2010·Journal of Clinical Oncology

Abstract

Purpose: Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22 + B-cell non-Hodgkin's lymphoma (NHL). Patients and Methods: Inotuzumab ozogamicin was administered intravenously as a single agent once every 3 or 4 weeks at doses ranging from 0.4 to 2.4 mg/m 2 . Outcomes included MTD, safety, pharmacokinetics, response, progression-free survival (PFS), and overall survival. Results: Seventy-nine patients were enrolled. The MTD was determined to be 1.8 mg/m 2 . Common adverse events at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each). The objective response rate at the end of treatment was 39% for the 79 enrolled patients, 68% for all patients with follicular NHL treated at the MTD, and 15% for all patients with diffuse large B-cell lymphoma treated at the MTD. Median PFS was 317 days (approximately 10.4 months) and 49 days for patients with follicular NHL and diffuse large B-cell lymphoma, respectively. Conclusion: Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell NHL, with reversible thrombocytopenia as the main toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.25.1900

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 336

Metadata

Authors
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I. G. H., Schuler, M., Sierra, J., Smith, M. R., Verhoef, G., Winter, J. N., Boni, J., Vandendries, E., Shapiro, M., & Fayad, L.
Venue
Journal of Clinical Oncology
Published
2010-04-20
Volume
28
Issue
12
Pages
2085-2093
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2126855868
Cited by
336
References
1
FWCI
21.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. https://app.cochat.ai/papers/10.1200/jco.2009.25.1900
The paper
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I. G. H., Schuler, M., Sierra, J., Smith, M. R., Verhoef, G., Winter, J. N., Boni, J., Vandendries, E., Shapiro, M., & Fayad, L. (2010). Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.25.1900

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.